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1. INTRODUCTION {#cam42002-sec-0005}
===============

Ewing sarcoma (EwS) is the second most common malignant bone tumor in childhood, predominantly affecting children and young adults.[1](#cam42002-bib-0001){ref-type="ref"} Histologically, small blue round cells are noted. Up to 95% of patients harbor the characteristic chromosomal 11q22q translocation.[2](#cam42002-bib-0002){ref-type="ref"}

The backbone of EwS treatment is induction chemotherapy that treats micrometastatic disease and reduces tumor volume to facilitate surgical procedures. Induction chemotherapy is followed by local therapy (surgery and/or radiotherapy) and maintenance chemotherapy. This multimodal treatment has greatly improved survival rate for EwS patients. Overall survival (OS) for patients with localized disease is approximately 70%‐75%; however, still below 30% for patients with metastatic disease.[1](#cam42002-bib-0001){ref-type="ref"}, [3](#cam42002-bib-0003){ref-type="ref"}

In the daily clinic, there is a need for prognostic factors that give an early indication whether response of the tumor to induction chemotherapy is adequate or whether chemotherapy should be adjusted in case of inadequate response. Histological response (HisRes) has been identified as a prognostic factor for outcome;[4](#cam42002-bib-0004){ref-type="ref"}, [5](#cam42002-bib-0005){ref-type="ref"} however, histological response is known late in the treatment, after induction chemotherapy and after local therapy has been performed, and cannot be identified in patients only receiving radiotherapy.

At diagnosis of EwS there is often major soft tissue involvement, which substantially contributes to the total tumor volume. After induction chemotherapy, there is usually a decrease in the soft tissue component, whereas the bony component shows little regression, probably due to the slow regression of the osteoid matrix.[6](#cam42002-bib-0006){ref-type="ref"}, [7](#cam42002-bib-0007){ref-type="ref"}, [8](#cam42002-bib-0008){ref-type="ref"} Based on the superior assessment of intramedullary and soft tissue extension, magnetic resonance imaging (MRI) is considered to be the modality of choice for local staging and response evaluation.[6](#cam42002-bib-0006){ref-type="ref"}, [9](#cam42002-bib-0009){ref-type="ref"}, [10](#cam42002-bib-0010){ref-type="ref"} Early modification of chemotherapy or an intensification of radiotherapy dosage could be potential options for patients with inadequate radiological response noted during early or late induction chemotherapy. Modification could exist of changing to second line agents or the addition of new, often targeted, agents.

Since HisRes has been identified as a prognostic factor, image‐based response might well correlate with HisRes.[11](#cam42002-bib-0011){ref-type="ref"}, [12](#cam42002-bib-0012){ref-type="ref"}, [13](#cam42002-bib-0013){ref-type="ref"}, [14](#cam42002-bib-0014){ref-type="ref"}, [15](#cam42002-bib-0015){ref-type="ref"}, [16](#cam42002-bib-0016){ref-type="ref"} Previously published reports on imaging based tumor response cited only limited numbers of patients and focused more on response during late induction chemotherapy.

This study aims to evaluate the prognostic value of the radiological tumor response with MRI during early and late induction chemotherapy with respect to survival and HisRes in a large cohort of patients with localized EwS. Patients were uniformly treated and included in the international EURO‐E.W.I.N.G.99 (EE99) trial with adequately long follow‐up.[17](#cam42002-bib-0017){ref-type="ref"}

2. METHODS {#cam42002-sec-0006}
==========

2.1. Study population {#cam42002-sec-0007}
---------------------

Data from consecutive Ewing sarcoma patients included in the EE99 trial between September 1999 and September 2009 were analyzed.[17](#cam42002-bib-0017){ref-type="ref"} Of these only patients with localized disease and all patients whose data contained 3D tumor volume measurements both at diagnosis and at least once during induction chemotherapy were included in the study. Patients who had received local therapy earlier than per protocol were excluded from the analysis. Primary EwS was confirmed by pathology and molecular diagnostics in all patients. All patients and/or legal guardians had given informed consent prior to study entry.

2.2. Treatment {#cam42002-sec-0008}
--------------

The EE99 protocol mandated 6 courses of induction chemotherapy consisting of vincristine, ifosfamide, doxorubicin, and etoposide (VIDE). Following local therapy, a risk‐adapted chemotherapy was administered. Protocol treatment details have been previously published.[17](#cam42002-bib-0017){ref-type="ref"}

2.3. Definitions {#cam42002-sec-0009}
----------------

### 2.3.1. Tumor volume {#cam42002-sec-0010}

Three‐dimensional tumor volume was calculated from MRI measurements (anteroposterior dimension x transverse x craniocaudal dimension). In the EE99 study a correction factor (F) was applied to elliptically shaped tumors (F = π/6 = 0.52) and to cylindrically shaped tumors (F = π/4 = 0.785). For all other tumor shapes, a correction factor of 0.63 (F = π/5) was applied. The same correction factor used for the MRI at diagnosis was used for subsequent MRIs. Changes in tumor volume were expressed as percentage involution. Adequate response (reduction ≥67%) and inadequate response (reduction \<67% or progressive disease) were delineated in line with cutoff values for partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) response assessment.[18](#cam42002-bib-0018){ref-type="ref"}, [19](#cam42002-bib-0019){ref-type="ref"}

### 2.3.2. Histological response {#cam42002-sec-0011}

Following induction chemotherapy, local therapy was performed. In patients who underwent surgery, the grade of histopathological response, that is, the percentage of viable tumor cells in the specimen, was determined according to the Salzer‐Kuntschik classification.[20](#cam42002-bib-0020){ref-type="ref"} A good response was defined as having less than 10% viable tumor cells (grade 1: no vital cells, grade 2: 1%‐4% vital cells, grade 3: 5%‐9% vital cells). A poor response was defined as having more than 10% viable tumor cells (grade 4: 10%‐50% cells, grade 5/6: \>50% vital cells).

### 2.3.3. Survival {#cam42002-sec-0012}

EFS time was defined as the interval between the first day of the first VIDE course and the date of first event or death. In the absence of events, patients were censored on the date of their most recent consultation. An event was defined as progressive disease, relapsed disease (local or metastatic), secondary malignancy, or death from any cause. OS was defined as the time from the first day of the first VIDE course until death from any cause. Patients with progressive disease (PD) at time of TVR assessment were excluded from analysis, as PD on therapy is known to be associated with poor outcome.

2.4. Statistical analyses {#cam42002-sec-0013}
-------------------------

Statistical analyses were performed using SPSS statistics 22 (IBM Corporation, Armonk, NY) and SAS 9.2 (SAS Institute, Cary, NC) software packages. EFS and OS were calculated using the Kaplan--Meier method. A log‐rank test was performed to determine statistical differences in the distribution of survival. Univariate comparisons between groups of patients and statistical significance were accomplished using log‐rank and chi‐square tests. Multivariate test procedures applied Cox and logistic regression analyses. The significance level was set at *P* \< 0.05 (two‐sided). Missing data were handled using list wise deletion.

3. RESULTS {#cam42002-sec-0014}
==========

From in total 1435 patients included in the EE99 trial, 907 patients had localized EwS. In 246 of the 907 patients the 3D tumor volume was calculated from MRI measurements taken at diagnosis and at least once during induction chemotherapy. Two patients who had received local or systemic therapy earlier than per protocol and 3 patients who had received initial surgery were excluded from analysis, so ultimately 241 patients were included in the study (Figure [1](#cam42002-fig-0001){ref-type="fig"}). Table [1](#cam42002-tbl-0001){ref-type="table"} shows the clinical baseline characteristics of these patients; these characteristics are consistent with previously published reports;[21](#cam42002-bib-0021){ref-type="ref"}, [22](#cam42002-bib-0022){ref-type="ref"} therefore, this study can be considered representative for the EE99 study cohort.

![Flow diagram of included patients. EwS, Ewing sarcoma, EE99, Euro‐Ewing 99 trial, TVR, tumor volume response](CAM4-8-1086-g001){#cam42002-fig-0001}

###### 

Characteristics of included EwS patients (n = 241)

  Patient characteristics                      Number (Total n = 241)   Percentage (%)
  -------------------------------------------- ------------------------ ----------------
  Age in years (median (range))                                         
  15.33 (0.42‐56 y)                                                     
  Gender                                                                
  Male                                         149                      61.8
  Female                                       92                       38.2
  Tumor volume at diagnosis (median (range))                            
  161 mL (0.7‐2717 mL)                                                  
  \< 200 mL                                    136                      56.4
  \>200 mL                                     105                      43.6
  Tumor form at diagnosis                                               
  Elliptic                                     151                      62.7
  Cylindrical                                  38                       15.8
  Unknown/missing                              52                       21.5
  Localization                                                          
  Pelvis                                       52                       21.6
  Abdomen                                      4                        1.7
  Spine                                        5                        2.0
  Thorax                                       55                       22.8
  Head and neck                                12                       5.0
  Upper extremity                              21                       8.7
  Lower extremity                              92                       38.2
  Soft tumor component                                                  
  Bone with or without soft tissue             215                      89.2
  Extra‐osseous                                25                       10.4
  Missing                                      1                        0.4
  Histopathology                                                        
  Undifferentiated EwS                         135                      56.0
  Neuro‐differentiated EwS/PNET                78                       32.4
  Large cell EwS                               3                        1.2
  Other EwS                                    17                       7.1
  Missing                                      8                        3.3
  Local therapy                                                         
  Surgery alone                                123                      51.0
  Surgery and radiotherapy                     95                       39.4
  Radiotherapy alone                           16                       6.6
  No local therapy                             4                        1.7
  Missing                                      3                        1.2
  Surgical resection                           Total n = 220            
  Radical resection                            164                      74.5
  Marginal resection                           39                       17.7
  Intralesional resection                      12                       5.5
  Missing                                      5                        2.3
  Histological response                        Total n = 220            
  [ Good: n = 151]{.ul}                                                 
  Grade 1: no vital cells                      100                      45.5
  Grade 2: 1%‐4% vital cells                   11                       5.0
  Grade 3: 5%‐9% vital cells                   39                       17.7
  Grade missing                                1                        0.5
  [Poor: n = 65]{.ul}                                                   
  Grade 4: 10%‐50% vital cells                 41                       18.6
  Grade 5/6: \>50% vital cells                 23                       10.5
  Grade missing                                1                        0.5
  Missing                                      4                        1.7
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In 129 of 241 included patients, 3D‐tumor volume measurement was performed at diagnosis, during early induction (course 1‐3) and during late induction phases (course 4‐6). If more than one MRI was performed during the early and/or late induction phase, only the data from the latest MRI were used. In 66 patients, an MRI was performed at diagnosis and only during early induction phase; in 46 patients, an MRI was done at diagnosis and only during late induction phase. For patients whose response was not measured with an MRI during the early induction phase (n = 46) or late induction phase (n = 66) other imaging modalities (often CT‐scan or ultrasound) were used for response assessment at these time points; these assessments were not reported in 3D. Ultimately, TVR was determined in 195 patients during early induction phase, and in 175 patients during late induction phase (Figure [1](#cam42002-fig-0001){ref-type="fig"}).

In patients with early TVR measurement (n = 193; excluding 2 patients with PD) median tumor reduction was 62%. In 80/193 patients (=41%), an adequate TVR was observed (median reduction = 83%). In the group with inadequate TVR (115/193 patients = 59%) the median reduction was 41%. During late induction phase the median reduction compared to diagnosis was 77% (n = 172; excluding 3 patients with PD). Adequate TVR was observed in 108/172 patients (=62%; median reduction 88%). In the 67/172 patients with an inadequate TVR the median reduction was 40%.

Of the 129 patients who had MRIs during both early and late induction phases, 4 patients showed progressive disease at time of late response assessment compared to their early response assessment. Overall, progression was observed in 9/241 patients (3.7%) during induction chemotherapy.

3.1. Combined evaluation of radiological and histological response {#cam42002-sec-0015}
------------------------------------------------------------------

Local resection was performed in 220/241 patients (91%); 151 of these 220 patients (70%) showed a good HisRes (see also Table [1](#cam42002-tbl-0001){ref-type="table"}). Table [2](#cam42002-tbl-0002){ref-type="table"} illustrates the TVR during early and late induction chemotherapy in relation with the HisRes determined in the patient group who underwent local resection. In the patients with early TVR measurement, 178/195 patients (91%) underwent local resection; however, histological data from 3/178 patients were missing; 122/175 (70%) of the remaining 175 patients showed a good HisRes. Of the 175 patients with TVR measurement during late induction phase, 161/175 (91%) underwent local resection; HisRes of 1 patient was missing. 111/160 patients (69%) showed a good HisRes. No correlation could be found between either early TVR (*P* = 0.92) or late TVR (*P* = 0.63) and histological response.

###### 

Tumor volume response (TVR) in patients who underwent surgical resection (n = 220) and correlation with histological response and TVR and relation to 3‐year Event Free Survival (EFS) and Overall Survival (OS) during early and late induction chemotherapy

  Histological response and relation with TVR   TVR and relation with outcome:3 years EFS and OS (SE)                                                                                                                                                                                                                                                            
  --------------------------------------------- --------------------------------------------------------------------------- ------------------------------------------------------------------------- ------------ --------------------------------- ----------------------------------------------------- ----------------------------------------------------- ---------------------------------------------------------------
  Early TVR measurement (n = 175)               n = 75 (43%)[good HR]{.ul}: n = 53 (71%) [poor HR:]{.ul}n = 22 (29%)        n = 100 (57%) [good HR]{.ul}: n = 69 (69%) [poor HR:]{.ul} n = 31 (31%)   *P* = 0.92   Early TVR measurement (n = 194)   n = 79 (41%) EFS 0.74 (SE 0.05)OS 0.74 (SE 0.05)      n = 115 (59%) EFS 0.72 (SE 0.05) OS 0.82 (SE 0.05)    *P* = 0.90 *P* = 0.37
  Late TVR measurement (n = 160)                n = 100 (62.5%) [good HR]{.ul}: n = 68 (68%) [poor HR:]{.ul} n = 32 (32%)   n = 60 (37.5%) [good HR]{.ul}: n = 43 (72%) [poor HR:]{.ul}n = 17 (28%)   *P* = 0.63   Late TVR measurement (n = 174)    n = 107 (61.5%) EFS 0.78 (SE 0.04) OS 0.8 (SE 0.04)   n = 67 (38.5%) EFS 0.61 (SE 0.06) OS 0.69 (SE 0.04)   *P* = 0.013[a](#cam42002-note-0003){ref-type="fn"} *P* = 0.26

HR, histological response.

Statistically significant.
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3.2. Factors related to outcome {#cam42002-sec-0016}
-------------------------------

### 3.2.1. Radiological response and survival {#cam42002-sec-0017}

Median follow‐up was 4.49 years (range 0.12‐13.2). Overall, 3‐year EFS was 0.71 (SE = 0.03) and OS 0.77 (SE = 0.03). This is in line with survival data previously reported from localized EwS patients in the EE99 trial.[21](#cam42002-bib-0021){ref-type="ref"}

### 3.2.2. Early TVR measurement and survival {#cam42002-sec-0018}

For the patient group with early TVR measurements available, survival data were known from 194/195 patients. In 79/194 (41%) of the patients, an adequate TVR was observed and 3‐year EFS was 0.74 (SE 0.05). In patients with early inadequate response, EFS was 0.72 (SE 0.04) (*P* = 0.90). Three‐year OS was 0.74 (SE 0.05) and 0.82 (SE 0.04), respectively (*P* = 0.37) (Table [2](#cam42002-tbl-0002){ref-type="table"}; Figure [2](#cam42002-fig-0002){ref-type="fig"}A).

![EFS (left) and OS (right) of patients with adequate and inadequate radiological response during (A) the early induction phase of chemotherapy (B) the late induction phase of chemotherapy](CAM4-8-1086-g002){#cam42002-fig-0002}

### 3.2.3. Late TVR and survival {#cam42002-sec-0019}

In the patient group with late TVR measurements available survival data from 174/175 patients were known. In 61.5% of these patients an adequate TVR was observed; the associated 3‐year EFS was 0.78 (SE 0.04) in contrast to 0.61 (SE 0.06) for patients with inadequate TVR (*P* = 0.013). Three‐year OS rate for patients with adequate TVR was 0.80 (SE 0.04) compared to 0.69 (SE 0.04) for patients with inadequate TVR (*P* = 0.26) (Table [2](#cam42002-tbl-0002){ref-type="table"}; Figure [2](#cam42002-fig-0002){ref-type="fig"}B).

3.3. Histological response and survival {#cam42002-sec-0020}
---------------------------------------

A good HisRes was observed in 151/216 patients (70%); associated 3‐year EFS was 0.77 (SE 0.04), whereas EFS was 0.54 (SE 0.07) in patients with poor HisRes (*P* = 0.001). Three‐year OS was 0.84 (SE 0.03) and 0.61 (SE 0.06), respectively (*P* = 0.001) (Figure [3](#cam42002-fig-0003){ref-type="fig"}).

![EFS (A) and OS (B) of patients who underwent local surgery (n = 220) with adequate versus inadequate histological response](CAM4-8-1086-g003){#cam42002-fig-0003}

3.4. Other factors associated with outcome {#cam42002-sec-0021}
------------------------------------------

Fifty‐six per cent of patients had a tumor volume \<200 mL; associated 3‐year EFS was 0.78 (SE 0.04); significantly better (*P* = 0.005) than EFS for 105 patients with an initial tumor volume ≥200 mL (EFS 0.62; SE 0.05). OS was 0.80 (SE 0.04) in patients with an initial tumor volume \<200 mL compared to 0.72 (SE 0.05) for patients with a tumor volume \>200 mL (*P* = 0.007).

No statistical difference (*P* = 0.66) was detected in EFS and OS between patients with osseous EwS (EFS 0.73; (SE 0.03); OS 0.77 (SE 0.03)) and extra‐osseous EwS (EFS 0.64; \[SE 0.10\]; OS 0.64 \[SE 0.1\] \[*P* = 0.33\]).

Three‐year EFS was 0.59 (SE 0.07) for patients with pelvic lesions. This was lower (*P* = 0.029) than EFS for EwS patients with other locations (EFS 0.73; SE 0.03). OS was 0.66 (SE 0.07) and 0.80 (SE 0.03), respectively (*P* = 0.04). Patients \<15 years of age had higher 3‐year EFS than patients ≥15 years: 0.77 (SE 0.04) compared to 0.64 (SE 0.05; *P* = 0.04). Three‐year OS was 0.83 (SE 0.04) and 0.70 (SE 0.04), respectively (*P* = 0.007). Three‐year EFS was 0.66 (SE 0.04) for males and 0.79 (SE 0.04) for females (*P* = 0.03). OS was 0.74 (SE 0.04) and 0.81 (SE 0.04), respectively (*P* = 0.26).

Surgery was radical in 164/214 patients (77%); marginal in 39/214 (18%) and intralesional in 11 patients (5%). Three‐year EFS was 0.73 (SE 0.04), 0.63 (SE 0.78), and 0.72 (SE 0.14), respectively (*P* = 0.65). Three‐year OS was 0.80 (SE 0.03), 0.66 (SE 0.08), and 0.70 (SE 0.14), respectively (*P* = 0.21).

3.5. Multivariate analysis {#cam42002-sec-0022}
--------------------------

Based on the factors associated with a significantly inferior 3‐year EFS in univariate analysis, a multivariate analysis was performed. Detailed results are shown in Table [3](#cam42002-tbl-0003){ref-type="table"}. A poor histological response after induction chemotherapy, a late 3D‐TVR and pelvic site were independent predictors for inferior EFS. For OS, poor HisRes and pelvic site were independent predictors (*P* \< 0.05; late inadequate TVR: *P* = 0.10).

###### 

Multivariate analysis by Cox regression of factors associated with disease outcome in patients with localized EwS during late induction phase (n = 175)

  Covariate                                         EFS    OS                                                                            
  ------------------------------------------------- ------ ----------- ---------------------------------------------- ------ ----------- ----------------------------------------------
  Age \> 15 years                                   1.04   0.56‐1.91   0.91                                           1.36   0.72‐2.58   0.35
  Sex                                               0.62   0.32‐1.19   0.15                                           0.89   0.47‐1.70   0.73
  Initial tumor volume \> 200 mL                    1.73   0.91‐3.30   0.10                                           1.58   0.81‐3.11   0.18
  Poor histological response (\>10% viable cells)   2.28   1.25‐4.15   0.007[a](#cam42002-note-0005){ref-type="fn"}   2.23   1.20‐4.15   0.011[a](#cam42002-note-0005){ref-type="fn"}
  Late inadequate tumor volume response (3D)        2.26   1.23‐4.15   0.008[a](#cam42002-note-0005){ref-type="fn"}   1.69   0.89‐3.2    0.10
  Pelvic location                                   2.80   1.49‐5.40   0.001[a](#cam42002-note-0005){ref-type="fn"}   2.44   2.44‐1.25   0.01[a](#cam42002-note-0005){ref-type="fn"}

CI, confidence interval; HR, Hazard ratio.

Difference *P* \< 0.05.

John Wiley & Sons, Ltd

4. DISCUSSION {#cam42002-sec-0023}
=============

Radiological response to chemotherapy as a prognostic factor for outcome has been described in several studies. In this study, we analyzed three‐dimensional tumor volume response in a large series of patients uniformly treated according to the Euro Ewing 1999 protocol to evaluate if early modification of chemotherapy could be an option in patients with an early inadequate TVR. However, we showed that early TVR is not related to prognosis nor to HisRes. Therefore, modification of chemotherapy in response to inadequate early TVR may not be justifiable. However, we did find that late inadequate TVR, poor HisRes and pelvic tumor location are independently associated with poor prognosis.

Studies concerning radiological TVR and correlation with survival were performed in small patient cohorts and showed inconsistent results.[11](#cam42002-bib-0011){ref-type="ref"}, [12](#cam42002-bib-0012){ref-type="ref"}, [13](#cam42002-bib-0013){ref-type="ref"}, [14](#cam42002-bib-0014){ref-type="ref"}, [15](#cam42002-bib-0015){ref-type="ref"}, [16](#cam42002-bib-0016){ref-type="ref"} In this respect, the large number of EwS patients included in our study is novel and adds to the available evidence. Limitations of this study include its retrospective nature; volume measurement was not centrally reviewed and a limited sample size of included patients when compared to the total number of patients included in the Euro Ewing 99 trial.

TVR may not adequately reflect the complex histological changes resulting from response to chemotherapy. Therefore, besides TVR, also the residual extramedullary tumor volume, calcification of residual tumor in soft tissue and medullary cavity, T2 signal variations, diffusion weighted imaging, and fludeoxyglucose positron emission tomography have been investigated as potential markers for response.[6](#cam42002-bib-0006){ref-type="ref"}, [7](#cam42002-bib-0007){ref-type="ref"}, [23](#cam42002-bib-0023){ref-type="ref"}, [24](#cam42002-bib-0024){ref-type="ref"}, [25](#cam42002-bib-0025){ref-type="ref"}, [26](#cam42002-bib-0026){ref-type="ref"}, [27](#cam42002-bib-0027){ref-type="ref"}, [28](#cam42002-bib-0028){ref-type="ref"}, [29](#cam42002-bib-0029){ref-type="ref"} Taking also (some of) these factors into account, a better prediction of tumor response in early induction might be possible. There is some debate as to which type of measurement (3D/2D/1D) is most valuable in assessing radiological response in solid tumors. Three‐dimensional tumor measurement has been shown to be more sensitive and accurate than 1D or 2D assessment in patients with other solid tumors,[26](#cam42002-bib-0026){ref-type="ref"}, [30](#cam42002-bib-0030){ref-type="ref"} whereas another study could not show a difference between 3D and 1D RECIST in rhabdomyosarcoma.[18](#cam42002-bib-0018){ref-type="ref"} Three‐dimensional TVR sensitivity might be more evident for tumors in which the axial tumor area changes more than the longitudinal dimension, which is commonly seen in bone tumors.[31](#cam42002-bib-0031){ref-type="ref"} Aghighi et al compared 1D, 2D, and 3D tumor measurements with clinical outcomes for EwS patients. Three‐dimensional tumor measurement was shown to be superior, and a higher correlation with clinical outcome was described.[16](#cam42002-bib-0016){ref-type="ref"}

In our study, 41% of patients achieved adequate TVR during the early phase of induction therapy and 62% during late induction phase. These percentages are slightly better than the TVR reported by Pan et al*,* [13](#cam42002-bib-0013){ref-type="ref"} who examined 66 localized and metastatic EwS patients prior to surgery. Nearly 40% of patients achieved at least partial remission (PR) according to RECIST criteria. An important question in daily clinical practice is whether early modification of chemotherapy is warranted in patients with early inadequate radiological tumor volume response. None of the previously published studies focused on TVR during early induction phase, where results of our study now show that TVR during early induction phase does not correlate with survival, and therefore modification of chemotherapeutic regimen should not be based on TVR during early induction phase. However, 3‐year EFS was higher for patients with adequate TVR measured late during induction chemotherapy, compared to patients with inadequate response at this time point. Furthermore, adequate TVR during either early or late chemotherapy induction phases was not a predictive marker for HisRes. This is in agreement with the observations of Pan et al.[13](#cam42002-bib-0013){ref-type="ref"} Abudu et al found a significant relationship between necrosis and 3D‐TVR;[12](#cam42002-bib-0012){ref-type="ref"} however, this study included only 50 EwS patients, both localized and metastatic, and used MRI or CT‐scan to determine TVR.

Similar to other studies,[4](#cam42002-bib-0004){ref-type="ref"}, [11](#cam42002-bib-0011){ref-type="ref"}, [12](#cam42002-bib-0012){ref-type="ref"}, [32](#cam42002-bib-0032){ref-type="ref"} we found that poor HisRes to induction chemotherapy correlated with poor outcome. In addition to poor HisRes and late inadequate TVR, initial tumor volume \>200 ml, age older than 15 years, pelvic location and male gender all appeared to be bad prognostic factors as determined with univariate analysis. These are all well‐known unfavorable prognostic factors.[2](#cam42002-bib-0002){ref-type="ref"}, [3](#cam42002-bib-0003){ref-type="ref"}, [21](#cam42002-bib-0021){ref-type="ref"}, [22](#cam42002-bib-0022){ref-type="ref"}, [32](#cam42002-bib-0032){ref-type="ref"} Multivariate analysis revealed that poor HisRes, pelvic location and late inadequate TVR were independently associated with poor prognosis. Based on EFS, patients with late inadequate TVR or poor HisRes on standard therapy, as a result of intrinsic tumor resistance to applied chemotherapeutic agents, could benefit from a more augmented therapy. For patients who receive radiotherapy only and therefore lack histological response as prognostic marker, late TVR may help to adequately stratify those patients for subsequent chemotherapy.

In conclusion, based on survival data, modifying chemotherapy based on inadequate early TVR may not be justifiable; however, patients with late‐phase inadequate TVR might benefit from augmented treatment.
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